Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
R
R
Danesi
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
M
M
Del Re
Clinical Pharmacokinetics, La Timone University Hospital, Marseille, and GPCO-Unicancer, Paris, France.
J
J
Ciccolini
Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
J H M
JHM
Schellens
Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and Department of Clinical Pharmacology, University Hospital, Tuebingen, Germany.
M
M
Schwab
IFCC Reference center - Pharmacogenetics, Department of Clinical Chemistry, Erasmus University, Rotterdam.
R H N
RHN
van Schaik
Department of Clinical Chemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
A B P
ABP
van Kuilenburg
D042943:Dihydrouracil Dehydrogenase (NADP); D004342:Drug Hypersensitivity; D005472:Fluorouracil; D006801:Humans; D011743:Pyrimidines
D011743:Pyrimidines; D042943:Dihydrouracil Dehydrogenase (NADP); D005472:Fluorouracil